On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > LATEST
LATEST
-
BUSINESS Chugai, UCSF Forge Multi-Year Drug Discovery Collab
August 17, 2026
-
BUSINESS Maruishi Gets Japan, Korea Rights to Adneuris Pain Drug
August 17, 2026
-
BUSINESS Wayrilz Offers Potential QOL Benefits for ITP Patients: Expert
August 17, 2026
-
REGULATORY Stelara IV Biosimilar Can Be Used for Crohn’s Induction: MHLW
August 17, 2026
-
REGULATORY PMDA Loses USB Containing Data on 286 People, 27 Companies
August 17, 2026
-
BUSINESS Keytruda Keeps Grip on Top Spot in July Drug Sales: Encise
August 17, 2026
-
BUSINESS Japan Ethical Drug Sales Jump 9% in June: Crecon
August 17, 2026
-
REGULATORY MHLW Panel Finalizes Exemptions for OTC-Like Drug Charges
August 17, 2026
-
REGULATORY Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
-
REGULATORY Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
-
REGULATORY Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
-
REGULATORY CEA Review Group Debates Draft Report, Eyes August 18 Wrap-Up
August 5, 2026
-
ORGANIZATION New Chuikyo Pharmacist Rep Urges 2027 Revision to Stay within 4-Minister Deal
August 3, 2026
-
REGULATORY Chuikyo OKs NHI Listing for Cuorips’ iPSC-Based Riheart
July 23, 2026
-
REGULATORY CEA Review Group Debates Comparator Technologies, ICER Uncertainty
July 14, 2026
-
REGULATORY Chuikyo Kicks Off Debate on FY2027 Off-Year Drug Price Revision
July 9, 2026
-
REGULATORY Boehringer’s Big-Seller Hopeful Jascayd Set for Listing, Haihe’s Haizexin Too
July 9, 2026
-
REGULATORY Chuikyo OKs NHI Listing for Ferring’s Adstiladrin, Ishin’s Allostem Sheet
July 9, 2026
-
REGULATORY Chuikyo OKs Drug Price Survey Plan for FY2027 Off-Year Revision
July 9, 2026
-
ORGANIZATION Labor Group Urges Govt to Scrap FY2027 Off-Year Drug Price Cuts
July 7, 2026
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…